<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2018.84008</article-id><article-id pub-id-type="publisher-id">HJBM-27282</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20180400000_21149554.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  以FXR为核心的胆汁酸代谢机制研究进展
  Advanced Progression in the Mechanism of Bile Acid Metabolism Targeting FXR
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>修利</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>思聪</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>庞</surname><given-names>博</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>宝龙</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>单</surname><given-names>毓娟</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>黑龙江中医药大学药物安全性评价中心，黑龙江 哈尔滨</addr-line></aff><aff id="aff1"><addr-line>哈尔滨工业大学食品科学与工程系，黑龙江 哈尔滨</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>10</month><year>2018</year></pub-date><volume>08</volume><issue>04</issue><fpage>62</fpage><lpage>68</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   胆汁酸是膳食脂质和脂溶性维生素在肠道消化吸收的重要生理因子，同时也可作为信号分子，调节人体内葡萄糖平衡、脂质代谢和能量消耗。胆汁酸代谢紊乱会导致一系列疾病。法尼醇X受体(farnesoid X receptor, FXR)是一种胆汁酸受体，可通过相应靶基因参与多种代谢通路调节，在胆汁酸代谢中发挥重要作用，有望作为治疗胆汁酸代谢紊乱相关疾病的新型药物靶点。本文就FXR在胆汁酸代谢中的调节作用及其机制进行综述，以期为制定胆汁酸代谢紊乱相关疾病的防治策略及其新药研发提供科学依据。 Bile acids are important physiological factors that facilitate the digestion &amp; absorption of dietary lipids and fat-soluble vitamins in the gut. In addition, they also act as signaling molecules to regulate glucose homeostasis, lipid metabolism and energy expenditure. Disorders of bile acid metabolism can lead to a series of diseases. The nuclear receptor farnesoid X receptor (FXR) is a specific bile acid receptor which plays an important role in the metabolism of bile acids through the regulation of multiple metabolic pathways and of corresponding target genes. Consequently, FXR is targeted to be a new drug for the therapy of disorders related to bile acid metabolism. This article reviews the recent progressions of FXR in regulating bile acid metabolism and its mechanism, which aims to provide scientific strategies for the prevention/treatment of bile acid metabolic disorders, and new drugs exploration. 
  
 
</p></abstract><kwd-group><kwd>胆汁酸，法尼醇X受体，胆汁酸代谢, Bile Acids</kwd><kwd> Farnesoid X Receptor</kwd><kwd> Bile Acid Metabolism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>以FXR为核心的胆汁酸代谢机制研究进展<sup> </sup></title><p>杨修利<sup>1</sup>，田思聪<sup>1</sup>，庞博<sup>1</sup>，李宝龙<sup>2</sup>，单毓娟<sup>1*</sup></p><p><sup>1</sup>哈尔滨工业大学食品科学与工程系，黑龙江 哈尔滨</p><p><sup>2</sup>黑龙江中医药大学药物安全性评价中心，黑龙江 哈尔滨</p><disp-formula id="hanspub.27282-formula31"><graphic xlink:href="//html.hanspub.org/file/2-1530110x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年10月4日；录用日期：2018年10月19日；发布日期：2018年10月26日</p><disp-formula id="hanspub.27282-formula32"><graphic xlink:href="//html.hanspub.org/file/2-1530110x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>胆汁酸是膳食脂质和脂溶性维生素在肠道消化吸收的重要生理因子，同时也可作为信号分子，调节人体内葡萄糖平衡、脂质代谢和能量消耗。胆汁酸代谢紊乱会导致一系列疾病。法尼醇X受体(farnesoid X receptor, FXR)是一种胆汁酸受体，可通过相应靶基因参与多种代谢通路调节，在胆汁酸代谢中发挥重要作用，有望作为治疗胆汁酸代谢紊乱相关疾病的新型药物靶点。本文就FXR在胆汁酸代谢中的调节作用及其机制进行综述，以期为制定胆汁酸代谢紊乱相关疾病的防治策略及其新药研发提供科学依据。</p><p>关键词 :胆汁酸，法尼醇X受体，胆汁酸代谢</p><disp-formula id="hanspub.27282-formula33"><graphic xlink:href="//html.hanspub.org/file/2-1530110x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1530110x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1530110x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>胆汁酸是胆汁中一大类胆烷酸的总称，是肝脏胆固醇分解代谢的最终产物。胆汁酸作为一种两亲分子，能够降低脂、水两相表面张力，从而促进膳食脂质和脂溶性维生素的消化、吸收与转运。其次，胆汁酸也可作为一种信号分子，通过激活核受体参与调节葡萄糖代谢、脂质代谢和能量代谢。胆汁酸淤积会对机体产生各种毒性作用，包括炎症、细胞凋亡和细胞死亡。此外，胆汁酸代谢紊乱会导致一系列疾病，包括胆汁淤积性肝病、高脂血症、脂肪肝疾病、心血管疾病和糖尿病等 [<xref ref-type="bibr" rid="hanspub.27282-ref1">1</xref>]。因此，维持胆汁酸的代谢平衡非常重要。法尼醇X受体(farnesoid X receptor, FXR)是核受体超家族的一员，广泛分布在肝、小肠等富含胆汁酸的器官中，胆汁酸是其内源性配体，因此FXR又被称为胆汁酸受体。FXR作为胆汁酸感受器，能够调节重要靶基因，在胆汁酸的合成、代谢及转运等过程中起重要的调控作用，有望作为治疗胆汁酸代谢紊乱相关疾病的新型药物靶点 [<xref ref-type="bibr" rid="hanspub.27282-ref2">2</xref>]。本文就FXR在胆汁酸代谢中的调节作用及其机制进行综述，以期为制定胆汁酸代谢紊乱相关疾病的防治策略及其新药研发提供科学依据。</p></sec><sec id="s4"><title>2. 胆汁酸的合成代谢及肠肝循环</title><p>两种主要胆汁酸——胆酸(cholic acid, CA)和鹅脱氧胆酸(chenodeoxycholic acid, CDCA)在肝脏中由胆固醇经两种途径合成。经典(或中性)途径是胆汁酸合成的主要途径，由肝细胞滑面内质网上的胆固醇7α-羟化酶(cholesterol 7α-hydroxylase, CYP7A1)启动，后经一系列反应生成初级胆汁酸：CA和CDCA。CYP7A1是胆汁酸合成的唯一限速酶。在该途径中，产生CA和CDCA的比例由微粒体甾醇12α-羟化酶(sterol 12α-hydroxylase, CYP8B1)决定，CYP8B1是CA合成必需酶，反应若缺少CYP8B1参与，则产生CDCA。替代(或酸性)途径由线粒体上的甾醇27α-羟化酶(sterol 27-hydroxylase, CYP27A1)启动，后经氧甾醇12α-羟化酶(oxysterol 7α-hydroxylase, CYP7B1)催化，最终生成CDCA。CYP27A1广泛存在于大多数组织和巨噬细胞中。替代途径仅占人体肝细胞总胆汁酸合成的9%左右，但在经典途径障碍时，替代途径会被上调，成为肝病患者主要的胆汁酸合成途径 [<xref ref-type="bibr" rid="hanspub.27282-ref3">3</xref>]。肝脏合成的CA和CDCA以酰胺键与牛磺酸/甘氨酸或硫酸盐/葡萄糖醛酸结合形成初级结合型胆汁酸，也称胆汁盐。结合型胆汁酸pKa低，溶解度大，有助于十二指肠酸性环境中胶束的形成，防止胆汁酸从胆道和小肠吸收，保证从回肠末端重吸收，在酸或Ca<sup>2+</sup>存在时不易沉淀出来。胆汁盐由胆盐输出泵(bile salt export protein, BSEP)、多药耐药相关蛋白2 (multidrug resistance-related protein 2, MRP2)、多药耐药蛋白3 (multidrug resistant protein 3, MDR3)经胆小管进入胆囊转运至胆汁中，摄食后随胆汁分泌进入十二指肠参与脂质和脂溶性维生素A、D、E、K的消化、吸收与转运 [<xref ref-type="bibr" rid="hanspub.27282-ref4">4</xref>]。</p><p>90%~95%的胆汁盐在回肠末端经小肠刷状缘顶端钠依赖型胆汁酸转运体(apical sodium dependent transporter, ASBT)主动吸收进入肠上皮细胞，并与回肠胆汁酸结合蛋白(ileum bile acid binding protein, IBABP)结合，IBABP可以促进胆汁盐穿过肠细胞向基底外侧膜转运，胆汁盐随后在回肠基底层的异二聚体有机溶质转运蛋白α/β (organic solute transporter α and β dimer, OSTα/OSTβ)作用下进入门静脉。一小部分胆汁盐在结肠经肠道微生物胆汁盐水解酶(bile salt hydrolase, BSH)解偶联，后经细菌7α-脱羟酶转化生成次级胆汁酸：脱氧胆酸(deoxycholic acid, DCA)和石胆酸(lithocholic acid, LCA)。次级胆汁酸或由被动吸收进入门静脉或随粪便排出体外。重吸收的初级和次级胆汁酸经门静脉循环至肝窦，并由Na<sup>+</sup>-牛磺胆酸盐转运多肽(Na<sup>+</sup>-taurocholatecotransporting polypeptide, NTCP)和有机阴离子转运多肽(organic anion transporters, OATPs)分别转运至肝细胞，在肝脏中，胆汁酸被重新结合，与新合成的胆汁盐一起再排入肠道，完成胆汁酸的一个肠肝循环 [<xref ref-type="bibr" rid="hanspub.27282-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.27282-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.27282-ref6">6</xref>]。人体胆汁酸库含2~4 g胆汁酸，肠肝循环每天发生6~10次，在粪便中丢失的胆汁酸(0.2~0.6 g/d)由肝脏从头合成补充，以保持恒定的胆汁酸库 [<xref ref-type="bibr" rid="hanspub.27282-ref7">7</xref>]。肝脏从门静脉回收胆汁酸(胆汁酸浓度10~80 μM)是不完全的，存在低水平的胆汁酸(胆汁酸浓度2~10 μM)在外周循环中，在通过肾脏中的肾小管时被重新吸收循环回肝脏 [<xref ref-type="bibr" rid="hanspub.27282-ref8">8</xref>]。</p></sec><sec id="s5"><title>3. 胆汁酸的微生物修饰</title><p>肠道微生物群在胆汁酸代谢中发挥重要作用。肠道微生物群将结合型胆汁酸解偶联变成游离型胆汁酸，后者在细菌7α-脱羟酶的作用下进一步转化为次级胆汁酸。胆汁酸解偶联是通过具有BSH活性的细菌进行的 [<xref ref-type="bibr" rid="hanspub.27282-ref9">9</xref>]。BSH是N端亲核(N-terminal nucleophile, Ntn)水解酶超家族蛋白质的微生物酶，特别切割甘氨酸和牛磺酸与胆汁盐的类固醇核结合部分的酰胺键，具有底物特异性。已经鉴定具有BSH活性的细菌大多为拟杆菌属(Bacteroides)、梭菌属(Clostridium)、双歧杆菌属(Bifidobacterium)、乳酸杆菌属(Lactobacillus)和肠球菌属(Enterococcus)等革兰氏阳性细菌，在一些共生的革兰氏阴性拟杆菌属中也检测到BSH [<xref ref-type="bibr" rid="hanspub.27282-ref10">10</xref>]。已知肠道中的胆汁盐对细菌有一定毒性，特别是在低pH下，影响胃肠道不同区域的细菌生长。BSH可以通过胆汁酸解偶联赋予一些细菌物种保护作用，并有助于在低pH下肠道菌群对胆汁酸的耐受性。由于BSH与肠道生存转运能力相关，因此BSH活性经常包括在益生菌的选择标准内 [<xref ref-type="bibr" rid="hanspub.27282-ref11">11</xref>]。</p><p>最近研究表明，肠道微生物群不仅影响胆汁酸库的组成，还影响胆汁酸激活受体FXR信号通路表达 [<xref ref-type="bibr" rid="hanspub.27282-ref12">12</xref>]。与具有正常菌群的大鼠相比，无菌大鼠各种组织中胆汁酸水平降低，游离型胆汁酸和甘氨酸偶联的胆汁盐几乎完全丧失，牛磺酸偶联的胆汁盐显着增加，同时受胆汁酸激活受体FXR调控的基因在肝中的表达发生变化。相反，无菌C57BL/6小鼠肝脏中的胆汁酸水平较正常菌群小鼠显着增加 [<xref ref-type="bibr" rid="hanspub.27282-ref13">13</xref>]。两项研究都表明肠道微生物群是胆汁酸代谢和功能的重要调节剂。肠道微生物群修饰胆汁酸分子的结构，影响FXR对胆汁酸合成通路的调节。</p></sec><sec id="s6"><title>4. 以FXR为核心的胆汁酸代谢机制研究</title><p>FXR是一种配体依赖性转录因子，又称为胆汁酸受体，广泛分布在肝、小肠等富含胆汁酸的器官中。最有效的FXR内源性配体是CDCA，其次是DCA，LCA和CA。FXR的人工合成激动剂有GW4064、6α-乙基去氧胆酸(6-ECDCA；又称INT-747或奥贝胆酸)、fexaramine和GSK2324 [<xref ref-type="bibr" rid="hanspub.27282-ref14">14</xref>]。UDCA不激活FXR，反而抑制FXR激活。受配体诱导后，FXR可形成核受体单体、同源二聚体或与视黄醇衍生物X受体(retinoid X receptor, RXR)形成异二聚体复合物，结合到靶基因启动子中一个碱基间隔的反向重复序列(inverted repeat-1, IR-1, AGGTCAnTGACCT)上，激活靶基因转录，因而在胆汁酸的合成、代谢及转运等过程中起重要的调控作用 [<xref ref-type="bibr" rid="hanspub.27282-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.27282-ref15">15</xref>]。</p><sec id="s6_1"><title>4.1. FXR对胆汁酸合成酶的作用及机制</title><p>20世纪60年代首次描述了胆汁酸依赖性负反馈环路，啮齿类动物口服胆汁酸可通过抑制Cyp7a1直接或间接抑制胆汁酸合成 [<xref ref-type="bibr" rid="hanspub.27282-ref16">16</xref>]。在敲除Fxr基因的小鼠(Fxr<sup> −/−</sup>)中，胆汁酸抑制Cyp7a1 mRNA的水平大大减弱，证明了FXR在胆汁酸合成中的关键作用 [<xref ref-type="bibr" rid="hanspub.27282-ref17">17</xref>]。导致胆汁酸合成酶受到抑制的负反馈作用主要涉及以下两种机制。</p><p>在肝脏中，过多的胆汁酸激活FXR，诱导小异二聚体伴侣(small heterodimer partner, SHP)的表达增加，SHP是一种没有DNA结合域的非典型受体，能与多种核受体形成二聚体并抑制其活性。SHP与肝受体同系物-1 (liver receptor homolog-1, LRH-1)形成抑制性复合物，LRH-1是胆汁酸合成关键酶CYP7A1的启动子，此复合物阻断Cyp7a1和其他LRH-1靶基因如Cyp8b1和Shp本身的转录，从而抑制胆汁酸合成。SHP也可与肝细胞核因子4α (hepatocyte nuclear factor 4α, HNF4α)结合，阻断HNF4α与过氧化物酶体(peroxisome proliferator-activated receptor γ coactivator 1α, PGC-1α)的相互作用，并抑制Cyp7a1和Cyp8b1的转录 [<xref ref-type="bibr" rid="hanspub.27282-ref18">18</xref>]。然而，用胆汁酸处理Shp<sup> −/−</sup>小鼠发现Cyp7a1和Cyp8b1 mRNA水平仍存在部分阻遏，表明胆汁酸对Cyp7a1和Cyp8b1的转录抑制存在其他不依赖于SHP的途径 [<xref ref-type="bibr" rid="hanspub.27282-ref19">19</xref>]。</p><p>在小肠中，FXR诱导成纤维细胞生长因子15/19 (fibroblast growth factor 15/19, FGF15/19)与肝细胞质膜上的FGFR4/β-Klotho复合物结合，启动细胞外信号调节激酶1/2 (extracellular signal-regulated kinase 1/2, ERK1/2)和c-Jun氨基末端激酶(Jun-N-terminal kinase, JNK)信号通路，抑制Cyp7a1表达和胆汁酸合成 [<xref ref-type="bibr" rid="hanspub.27282-ref20">20</xref>]。负反馈抑制胆汁酸合成的第二种机制是基于观察到FXR激动剂GW4064诱导肠激素FGF15分泌，后者激活肝FGF受体4 (FGF receptor 4, FGFR4)，最终抑制Cyp7a1mRNA表达 [<xref ref-type="bibr" rid="hanspub.27282-ref21">21</xref>]。随后的研究表明，FXR诱导小鼠肠道中Fgf15 mRNA (人类同系物Fgf19)的表达，且与肝脏中Cyp7a1mRNA表达水平呈负相关。在Fgfr4<sup> −/−</sup>和Fgf15<sup>−/−</sup>小鼠中，胆汁酸库、粪便胆汁酸分泌以及Cyp7a1表达水平都增加，表明FGF15/FGFR4信号通路抑制Cyp7a1表达以调节胆汁酸代谢。此外，GW4064抑制肝Fxr<sup>−/−</sup>小鼠中Cyp7a1表达，但不抑制肠Fxr<sup>−/−</sup>小鼠中Cyp7a1表达。有趣的是，FXR介导的Cyp8b1表达抑制相较于肠FXR更依赖肝FXR，而FGF15抑制Cyp7a1而不抑制Cyp8b1表达 [<xref ref-type="bibr" rid="hanspub.27282-ref9">9</xref>]。这些结果有力的表明，小肠FXR (而不是肝FXR)是胆汁酸抑制Cyp7a1基因转录所必需的。FGF19激活FGFR4信号传导需要膜结合糖苷酶β-Klotho。在β-Klotho<sup>−/−</sup>小鼠中，胆汁酸合成、分泌和Cyp7a1表达增加，但Cyp8b1表达没有改变 [<xref ref-type="bibr" rid="hanspub.27282-ref22">22</xref>]。</p></sec><sec id="s6_2"><title>4.2. FXR对胆汁酸肠肝循环相关载体的作用及机制</title><p>FXR的胆汁酸依赖性激活还调节胆汁酸肠肝循环的相关载体，以维持胆汁酸的代谢平衡，避免胆汁淤积。主要包括以下机制 [<xref ref-type="bibr" rid="hanspub.27282-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.27282-ref23">23</xref>]。</p><sec id="s6_2_1"><title>4.2.1. 上调肝脏分泌载体表达，促进肝脏分泌胆汁酸</title><p>在肝脏中，激活的FXR诱导运载蛋白BSEP和MDR2/3表达，其分别用于将胆汁盐、磷脂酰胆碱流入胆小管。BSEP是主要的胆汁酸外排泵，利用ATP水解来分泌结合型胆汁酸，抗胆汁酸浓度比肝细胞高约1000倍。FXR还诱导MRP2，其排出葡糖醛酸化和硫酸化胆汁酸、有机阴离子和药物。FXR通过上调肝脏分泌载体的表达，促进肝脏分泌胆汁酸。</p></sec><sec id="s6_2_2"><title>4.2.2. 上调肠道重吸收载体表达，促进胆汁酸肠道重吸收</title><p>结合型胆汁酸在回肠首先通过 ASBT被主动重吸收入小肠黏膜细胞，由于胆汁酸不能透过细胞膜，需要借助IBABP将胆汁酸穿过小肠黏膜细胞肠腔面向基底外侧膜转运，随后在基底层的OSTα/OSTβ作用下进入门静脉。FXR的激活可以诱导IBABP表达，使其结合胆汁酸，有助于胆汁酸在小肠内的转运，同时促进OSTα/OSTβ表达，使胆汁酸重吸收进入门静脉。OSTα/OSTβ是肠中主要的胆汁酸外排转运蛋白，也可作为肝窦性膜中的次级胆汁酸外排转运蛋白。</p></sec><sec id="s6_2_3"><title>4.2.3. 下调肝脏重吸收载体表达，抑制胆汁酸肝脏重吸收</title><p>肠道重吸收的胆汁酸通过门静脉血循环至肝脏，在主要载体NTCP和次要载体OATP的作用下重吸收进入肝细胞。FXR抑制NTCP和OATP的基因转录，抑制胆汁酸重摄取回肝脏，避免高浓度的胆汁酸对肝脏的毒性。FXR诱导的转录阻遏物SHP的表达增加，是NTCP受到抑制的主要机制。</p><p>FXR通过调节胆汁酸合成、肝脏胆汁酸分泌、肠胆汁酸重吸收和分泌以及胆汁酸重摄入肝细胞，在胆汁酸的肠肝循环中起关键作用 [<xref ref-type="bibr" rid="hanspub.27282-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.27282-ref24">24</xref>]。FXR靶基因缺陷性调节会损害胆汁酸的肠肝循环，并导致包括胆汁淤积性肝病在内的一系列代谢性疾病。</p></sec></sec><sec id="s6_3"><title>4.3. FXR激动剂作为胆汁酸代谢相关疾病治疗靶点的潜力</title><p>许多研究表明FXR的激活抑制肝和肠中的炎症，并且FXR激动剂是用于代谢和炎性疾病的潜在治疗药物 [<xref ref-type="bibr" rid="hanspub.27282-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.27282-ref26">26</xref>]。奥贝胆酸(Obeticholic acid, OCA)是一种有效且具有选择性的FXR人工合成激动剂，具有抗胆碱作用。在动物研究中，OCA可增加胰岛素敏感性，抑制糖异生和脂肪生成，并具有抗炎和抗纤维化特性 [<xref ref-type="bibr" rid="hanspub.27282-ref27">27</xref>]。OCA在治疗胆汁淤积方面的潜在益处已在实验动物模型和人类中广泛研究。最近的临床试验报道，OCA显着改善肝功能，并降低原发性胆汁性肝硬化患者血清碱性磷酸酶、谷氨酰转移酶和丙氨酸转氨酶活性，被FDA批准用于治疗原发性胆汁性肝硬化患者 [<xref ref-type="bibr" rid="hanspub.27282-ref28">28</xref>]。此外，OCA在临床试验中改善了非酒精性脂肪性肝炎评分，是非酒精性脂肪性肝炎有希望的疗法 [<xref ref-type="bibr" rid="hanspub.27282-ref29">29</xref>]。</p></sec></sec><sec id="s7"><title>5. 总结与展望</title><p>胆汁酸是调节营养吸收和葡萄糖积累、脂质和能量代谢的重要生理因素。维持胆汁酸稳态对于防止胃肠道胆汁酸毒性和炎症至关重要，同时胆汁酸在维持代谢稳态和预防代谢紊乱中发挥重要作用。近年来随着对FXR研究的深入，人们对FXR在胆汁酸代谢中的调控作用越来越关注，FXR有望作为治疗胆汁酸代谢相关疾病的新型药物靶点。目前，在FXR的研究中仍存在以下问题。其一，FXR在机体内有太多的靶基因，仍有部分与FXR作用相关的靶基因尚待进一步被发现，同时FXR作用于一些靶基因的具体途径不清楚，需进一步研究。其二，选择性的调控FXR部分靶基因的新型激动剂也有待于继续探讨和发现。其三，参与胆汁酸调节的核受体除了FXR还有其它核受体如G蛋白偶联受体、孕烷X受体、维生素D受体，在探讨胆汁酸代谢时还应考虑FXR与其它核受体之间的作用。</p></sec><sec id="s8"><title>基金项目</title><p>国家自然科学基金资助项目(No. 81573135)。</p></sec><sec id="s9"><title>文章引用</title><p>杨修利,田思聪,庞 博,李宝龙,单毓娟. 以FXR为核心的胆汁酸代谢机制研究进展Advanced Progression in the Mechanism of Bile Acid Metabolism Targeting FXR[J]. 生物医学, 2018, 08(04): 62-68. https://doi.org/10.12677/HJBM.2018.84008</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.27282-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chiang, J.Y.L. (2013) Bile Acid Metabolism and Signaling. Comprehensive Physiology, 3, 1191-1212.  
&lt;br&gt;https://doi.org/10.1002/cphy.c120023</mixed-citation></ref><ref id="hanspub.27282-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ferrebee, C.B. and Dawson, P.A. (2015) Metabolic Effects of Intestinal Absorption and Enterohepatic Cycling of Bile Acids. Acta Pharmaceutica Sinica B, 5, 129-134. &lt;br&gt;https://doi.org/10.1016/j.apsb.2015.01.001</mixed-citation></ref><ref id="hanspub.27282-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chiang, J.Y.L. (2017) Bile Acid Metabolism and Signaling in Liver Disease and Therapy. Liver Research, 1, 3-9.  
&lt;br&gt;https://doi.org/10.1016/j.livres.2017.05.001</mixed-citation></ref><ref id="hanspub.27282-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dawson, P.A. and Karpen, S.J. (2015) Intestinal Transport and Metabolism of Bile Acids. The Journal of Lipid Research, 56, 1085-1099. &lt;br&gt;https://doi.org/10.1194/jlr.R054114</mixed-citation></ref><ref id="hanspub.27282-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">皮宇, 高侃, 朱伟云. 机体胆汁酸肠–肝轴的研究进展[J]. 生理科学进展, 2017, 48(3): 161-166.</mixed-citation></ref><ref id="hanspub.27282-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">De Aguiar Vallim, T.Q., Tarling, E.J. and Edwards, P.A. (2013) Pleiotropic Roles of Bile Acids in Metabolism. Cell Metabolism, 17, 657-669. &lt;br&gt;https://doi.org/10.1016/j.cmet.2013.03.013</mixed-citation></ref><ref id="hanspub.27282-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Dawson, P.A., Hubbert, M.L. and Rao, A. (2010) Getting the Most from OST: Role of Organic Solute Transporter, OSTα-OSTβ, in Bile Acid and Steroid Metabolism. Biochimica et Biophysica Acta, 1801, 994-1004.  
&lt;br&gt;https://doi.org/10.1016/j.bbalip.2010.06.002</mixed-citation></ref><ref id="hanspub.27282-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y.-K.J., Guo, G.L. and Klaassen, C.D. (2011) Diurnal Variations of Mouse Plasma and Hepatic Bile Acid Concentrations as Well as Expression of Biosynthetic Enzymes and Transporters. PLoS One, 6, e16683.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0016683</mixed-citation></ref><ref id="hanspub.27282-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wahlström, A., SayinSama, I., Marschall, H.-U., et al. (2016) Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metabolism, 24, 41-50. &lt;br&gt;https://doi.org/10.1016/j.cmet.2016.05.005</mixed-citation></ref><ref id="hanspub.27282-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Long, S.L., Gahan, C.G.M. and Joyce, S.A. (2017) Interactions between Gut Bacteria and Bile in Health and Disease. Molecular Aspects of Medicine, 56, 54-65. &lt;br&gt;https://doi.org/10.1016/j.mam.2017.06.002</mixed-citation></ref><ref id="hanspub.27282-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jones, B.V., Begley, M., Hill, C., et al. (2008) Functional and Comparative Metagenomic Analysis of Bile Salt Hydrolase Activity in the Human Gut Microbiome. Proceedings of the National Academy of Sci-ences USA, 105, 13580-13585. &lt;br&gt;https://doi.org/10.1073/pnas.0804437105</mixed-citation></ref><ref id="hanspub.27282-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fiorucci, S. and Distrutti, E. (2015) Bile Ac-id-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends in Molecular Medicine, 21, 702-714. &lt;br&gt;https://doi.org/10.1016/j.molmed.2015.09.001</mixed-citation></ref><ref id="hanspub.27282-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Swann, J.R., Want, E.J., Geier, F.M., et al. (2011) Systemic Gut Microbial Modulation of Bile Acid Metabolism in Host Tissue Compartments. Proceedings of the National Academy of Sciences USA, 108, 4523-4530.  
&lt;br&gt;https://doi.org/10.1073/pnas.1006734107</mixed-citation></ref><ref id="hanspub.27282-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Porez, G., Prawitt, J., Gross, B., et al. (2012) Bile Acid Receptors as Targets for the Treatment of Dyslipidemia and Cardiovascular Disease: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases. The Journal of Lipid Research, 53, 1723-1737. &lt;br&gt;https://doi.org/10.1194/jlr.R024794</mixed-citation></ref><ref id="hanspub.27282-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cariello, M., Piccinin, E., Garcia-Irigoyen, O., et al. (2018) Nuclear Receptor FXR, Bile Acids and Liver Damage: Introducing the Progressive Familial Intrahepatic Cholestasis with FXR Mutations. Biochimica et Biophysica Acta, 1864, 1308-1318. &lt;br&gt;https://doi.org/10.1016/j.bbadis.2017.09.019</mixed-citation></ref><ref id="hanspub.27282-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Russell, D.W. (2003) The Enzymes, Regulation, and Genetics of Bile Acid Synthesis. Annual Review of Biochemistry, 72, 137-174. &lt;br&gt;https://doi.org/10.1146/annurev.biochem.72.121801.161712</mixed-citation></ref><ref id="hanspub.27282-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">SayinSama, I., Wahlström, A., Felin, J., et al. (2013) Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metabolism, 17, 225-235.  
&lt;br&gt;https://doi.org/10.1016/j.cmet.2013.01.003</mixed-citation></ref><ref id="hanspub.27282-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">del Castillo-Olivares, A., Campos, J.A., Pandak, W.M., et al. (2004) The Role of alpha1-Fetoprotein Transcription Factor/LRH-1 in Bile Acid Biosynthesis: A Known Nuclear Receptor Activator That Can Act as a Suppressor of Bile Acid Biosynthesis. The Journal of Biological Chemistry, 279, 16813-16821. &lt;br&gt;https://doi.org/10.1074/jbc.M400646200</mixed-citation></ref><ref id="hanspub.27282-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Hagedorn, C.H. and Wang, L. (2011) Role of Nuclear Receptor SHP in Metabolism and Cancer. Biochimica et Biophysica Acta, 1812, 893-908. &lt;br&gt;https://doi.org/10.1016/j.bbadis.2010.10.006</mixed-citation></ref><ref id="hanspub.27282-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lin, B.C., Wang, M., Blackmore, C., et al. (2007) Liver-Specific Activities of FGF19 Require Klothobeta. The Journal of Biological Chemistry, 282, 27277-27284. &lt;br&gt;https://doi.org/10.1074/jbc.M704244200</mixed-citation></ref><ref id="hanspub.27282-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Holt, J.A., Luo, G., Billin, A.N., et al. (2003) Definition of a Novel Growth Factor-Dependent Signal Cascade for the Suppression of Bile Acid Biosynthesis. Genes &amp; Development, 17, 1581-1591. &lt;br&gt;https://doi.org/10.1101/gad.1083503</mixed-citation></ref><ref id="hanspub.27282-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ito, S., Fujimori, T., Furuya, A., et al. (2005) Impaired Negative Feedback Suppression of Bile Acid Synthesis in Mice Lacking beta-Klotho. Journal of Clinical Investigation, 115, 2202-2208. &lt;br&gt;https://doi.org/10.1172/JCI23076</mixed-citation></ref><ref id="hanspub.27282-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Halilbasic, E., Claudel, T. and Trauner, M. (2013) Bile Acid Transporters and Regulatory Nuclear Receptors in the Liver and Beyond. Journal of Hepatology, 58, 155-168. &lt;br&gt;https://doi.org/10.1016/j.jhep.2012.08.002</mixed-citation></ref><ref id="hanspub.27282-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, H. and Hylemon, P.B. (2014) Bile Acids Are Nutrient Signaling Hormones. Steroids, 86, 62-68.  
&lt;br&gt;https://doi.org/10.1016/j.steroids.2014.04.016</mixed-citation></ref><ref id="hanspub.27282-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Li, T. and Chiang, J.Y.L. (2014) Bile Acid Signaling in Metabolic Disease and Drug Therapy. Pharmacological Reviews, 66, 948-983. &lt;br&gt;https://doi.org/10.1124/pr.113.008201</mixed-citation></ref><ref id="hanspub.27282-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Molinaro, A., Wahlström, A. and Marschall, H.-U. (2018) Role of Bile Acids in Metabolic Control. Trends in Endocrinology &amp; Metabolism, 29, 31-41. &lt;br&gt;https://doi.org/10.1016/j.tem.2017.11.002</mixed-citation></ref><ref id="hanspub.27282-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Adorini, L., Pruzanski, M. and Shapiro, D. (2012) Farnesoid X Receptor Targeting to Treat Nonalcoholic Steatohepatitis. Drug Discovery Today, 17, 988-997. &lt;br&gt;https://doi.org/10.1016/j.drudis.2012.05.012</mixed-citation></ref><ref id="hanspub.27282-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Hirschfield, G.M., Mason, A., Luketic, V., et al. (2015) Efficacy of Obeticholic Acid in Patients with Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholicacid. Gastroenterology, 148, 751-761.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2014.12.005</mixed-citation></ref><ref id="hanspub.27282-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. (2013) Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastro-enterology, 145, 574-582.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2013.05.042</mixed-citation></ref></ref-list></back></article>